Yuhan Corp and BMS will copromote Sotyktu and Zeposia

The two companies signed a copromotion agreement

Will copromote plaque psoriasis drug ‘Sotyktu’ and ulcerative colitis drug ‘Zeposia’ from March

The collaboration is expected to accelerate the provision of the treatments, fueled by BMS Korea’s innovative capabilities and Yuhan Corp’s sales power

(From the left) Hye-Young Lee, Country Manager of BMS Korea and Wook-Je Cho, CEO of Yuhan Corp

Yuhan Corp (CEO: Wook-Je Cho) announced that the company has signed a copromotion agreement with BMS Korea (Country Manager: Hye-Young Lee) for BMS’s plaque psoriasis drug ‘Sotyktu (deucravacitinib)’ and ulcerative colitis drug ‘Zeposia (ozanimod)’ on the 11th.

 

This strategic partnership for joint sales and marketing in Korea marks the first partnership between the two companies and will begin in March.

 

Sotyktu is the first TYK2 inhibitor approved by the Ministry of Food and Drug Safety for moderate-to-severe plaque psoriasis in adults.

 

The convenient, once-daily oral treatment was approved by the MFDS in August 2023 for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy.

 

The drug’s efficacy and safety profile were demonstrated through the Phase III POETYK PSO-1 and POETYK PSO-2 clinical trials.

 

Zeposia is the first shingosine 1-phosphate receptor (S1P) modulator to be approved in Korea to treat moderate-to-severe active ulcerative colitis.

 

The drug was granted reimbursement in January of this year for the treatment of adult patients with moderate-to-severe active ulcerative colitis who have not had an adequate response to or are intolerant of conventional therapies (such as corticosteroids, 6-mercaptopurine or azathioprine) or for whom these agents are contraindicated.

 

Zeposia’s clinical efficacy and safety were confirmed through the ‘TRUE NORTH’ trial.

 

Wook-Je Cho, CEO of Yuhan Corp, said, “We expect the partnership and the innovative medicines will help us provide new therapeutic benefits to patients in Korea with plaque psoriasis and ulcerative colitis.” Hye-Young Lee, Country Manager of BMS Korea, said, “We look forward to promptly bringing the therapeutic benefits of the orally-administered, convenient Sotyktu and Zeposia to more patients in Korea, We will continue to work with other members of Korea’s healthcare ecosystem to improve patient access in a variety of disease areas with high unmet need."